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Abstract 
Osteoporosis is a chronic disease characterized by low bone mineral density (BMD) and 
micro-architectural deterioration and is especially prevalent in postmenopausal women. 
Soy isoflavones (i.e. “phytoestrogens”) have been proposed as a safe alternative to 
hormone replacement therapy for preventing loss of BMD. Exercise is also recommended 
for slowing the loss of BMD. The present research is a one year extension of a previous 
randomized controlled trial which measured bone loss in women who did or did not take 
isoflavone or exercised for two years. The present study consisted of 86 participants from 
the same previous groups with: n=28 exercised and did not take isoflavone; n=26 stopped 
isoflavone supplementation but continued to exercise; n=18 stopped isoflavone 
supplementation and did not exercise; and n=14 controls who did not exercise or take 
isoflavone. Exercise training included two one-hour resistance training sessions and four 
20-30 min brisk walking sessions per week. Areal BMD (aBMD) of the hip and lumbar 
spine, and fat and lean tissue mass were measured at baseline, and at one, two, and three 
years. There were exercise group x time interactions for total hip and lumbar spine BMD 
with it decreasing in the exercise groups compared to non-exercise groups (p<0.05). There 
were no changes in lean tissue mass but fat mass was reduced from a baseline of 25 ± 6.6 
kg in the exercise group after year one and this was maintained into year three (24 ± 7.1 
kg) (p < 0.01). The fat mass in the non-exercise groups increased from baseline (28.9 ± 6.7 
kg) to year three (30.3 ± 7.1 kg) (p < 0.01). There were also exercise group x time 
interactions for trunk and percent fat with more decreases in the exercise compared to non-
exercise groups. There were exercise x time interactions for muscular strength, with chest 
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press (upper body) and hack squat (lower body) strength 33% and 88% higher in exercise 
groups than non-exercise groups by the end of three years (p<0.01). We conclude that 
exercise and removal of isoflavone supplements did not stimulate or maintain aBMD 
beyond the first two years of training, but exercise did reduce whole body fat mass, trunk 
and percent fat, and led to increased muscular strength.  
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1. Introduction  
The skeleton, comprised of bone, is the scaffold on top of which the rest of the 
human body forms. Bone is a complex nanocomposite structure composed of both organic 
and inorganic entities (Wang et al., 2014).  The organic portion is largely type I collagen 
arranged into nanofibers ranging from 50 to 500 nm in diameter (Kadler, Holmes, Trotter, 
& Chapman, 1996) while the primary inorganic portion consists of hydroxyapatite crystals 
which are embedded between the collagen fibers (Wang et al., 2014). This interweaving of 
the organic and inorganic components provides architectural strength. Formation of bone, 
which is the deposition and resorption of the organic and inorganic components noted 
above, begins during fetal growth and continues into the second and third decade of life 
(Weaver et al., 2016). During childhood, bone mass develops slowly but accelerates prior 
and during pubertal growth spurt (Weaver et al., 2016). Peak bone mineral accretion rate 
occurs at approximately 12 years of age in girls and 14 in boys while approximately 95% 
of the total adult bone mass will have been acquired approximately four years after the 
peaks (Weaver et al., 2016). One of the most important factors in bone development is that 
it is sensitive to loading so that physical activity promotes bone modeling while a lack of 
activity slows bone accretion rates while also compromising its strength and flexibility 
(Rubin & Lanyon, 1984; Weaver et al., 2016).  
During aging, especially after the age of 50 (postmenopausal age), besides a 
decrease in muscle mass, there is also deterioration in bone mass and a weakened bone 
tissue microarchitecture which leads to bone fragility and a greater susceptibility to 
fractures (Figure 1) (Consensus Development Conference, 1993). This loss of bone tissue 
is termed osteoporosis, or “porous bone”, with the World Health Organization (WHO) 
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defining it as when areal bone mineral density (aBMD) is less than 2.5 standard deviations 
(S.D.) below that of the sex-specific mean of young adults (World Health Organisation, 
1994). In Canada, there is a high incidence of hip and other bone fractures as a result of 
osteoporosis.  In 1981, it was estimated that 20,000 people had hip fractures and this had 
increased to 27,342 in 1995, with 73% of the hip fractures occurring in women (Lorrain et 
al., 2003). However, between 1996 and 2005, fracture rates have declined annually by 2.4% 
in both men and women (Leslie et al., 2009). Although this may be encouraging, it should 
be noted that currently seniors comprise 16.9 percent of the Canadian population and this 
is projected to increase to 23 percent by 2031 (Sinha, 2013). This means that fracture rates 
due to osteoporosis may increase in the future. Moreover, these statistics mask the fact that 
there are minority populations within Canada who have significantly higher rates of 
fractures as compared to their average Canadian cohorts (Leslie et al., 2004). In First 
Nations Canadians, the standardized incidence ratios for each fracture type , as compared 
to average Canadians, were 1.93 for spine, 3.01 for wrist, 1.88 for hip, and 2.23 for all 
types of fracture (Leslie et al., 2004).  
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Figure 1: Bone microarchitectural deterioration at the distal radius illustrated as thin 
trabeculae and cortical shell in a 62 year old osteoporotic woman (left) versus 19 year old 
healthy female (right). Image courtesy of Dr. Kontulainen, University of Saskatchewan. 
 
Osteoporosis is a chronic illness that affects a large proportion of adults over the 
age of 50 with incidence rates being higher in women than men. In Canada in 2011, there 
were approximately 164,763 people who had a fracture with 69% of them being women 
while the rest, or 31%, were men (Hopkins et al., 2016). Of these, the number of fractures 
directly attributable to osteoporosis was estimated to be 131,443 (81%) with women twice 
as likely to have fractures as compared to men (Hopkins et al., 2016). Moreover, the 
fracture rates are positively correlated with age so that the elderly are more likely to have 
any types of fractures as compared to their younger same sex cohorts. Osteoporosis and 
the resultant fractures place a substantial economic burden on Canadian society. Acute care 
costs were estimated to be $1.5 billion (18% increase since 2008) in 2011 and when 
outpatient care, prescription drugs, secondary admissions, and indirect costs are added, the 
overall yearly cost of osteoporosis was estimated to be $4.63 billion (83% increase since 
2008) (Hopkins et al., 2016).  
Images of wrist showing lack of trabecular bone and thin 
cortical shell in an osteoporotic radius
Distal radius (High Resolution pQCT scans)
Healthy 
19 year old woman 
Osteoporotic 
62 year old women
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As one approaches the age of 50, there is a decline in bone formation, increased 
bone resorption, and loss of bone mass (Figure 2). This loss of bone is especially marked 
in women as compared to men. Women begin losing bone around the age of 35 at a rate of 
0.5% to 1% annually and this accelerates to 3% to 5% per year in the decade after 
menopause (Josse et al., 1996).  One of the main reasons ascribed to why women lose more 
bone mass as compared to men, especially after menopause, is due to a decrease in estrogen 
levels. It is known and generally accepted that estrogen plays a significant role in regulating 
bone homeostasis, especially given the fact that there are estrogen receptors on osteoblasts 
as well as osteoclasts (Lerner, 2006; Lindsay, 1995). Estrogen inhibits osteoclasts from 
dissolving and resorbing bone, and therefore increases or maintains bone structure and 
mass (Lerner, 2006). It is thought that estrogen causes apoptosis in osteoclasts and 
indirectly promotes osteoblast proliferation which then allows the human body, especially 
in females, to maintain or increase bone formation (Wang et al., 2015). In fact, one of the 
therapies used to stabilise osteoporosis is estrogen therapy (Klein-Nulend, van Oers, 
Bakker, & Bacabac, 2015).  
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Figure 2: Bone mass across the male and female lifespan. Figure from (Weaver et al., 
2016). 
Osteoporosis is also common in postmenopausal women because concomitant with 
hormonal changes, such as a decrease in estrogen, there is reduced mobility. As noted 
above, bone formation is stimulated by mechanical load and stress and because this 
becomes reduced with age, the result is a decrease in bone formation (Klein-Nulend, 
Bacabac, & Bakker, 2012). It is known that stress from exercise subjects bone to strain and 
this results in a biochemical signal to stimulate osteocytes and initiate bone formation and 
remove damaged bone (Frost, 1992). However, postmenopausal estrogen deficiency causes 
bone to be less sensitive to mechanical force, resulting in decreased BMD even with a 
constant load. Therefore, a combined therapy of exercise and estrogen replacement could 
be the optimal intervention to maintain bone mass and offset bone loss in postmenopausal 
women.  
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One promising treatment for osteoporosis, or to at least maintain adequate BMD, 
is the use of phytoestrogens (Wang, Sathyamoorthy, & Phang, 1996). Phytoestrogens are 
naturally occurring, plant produced bioactive compounds which have antioxidant and 
antibiotic properties, as well as the ability to decrease male fertility in herbivores as a 
defense against herbivore overpopulation, and therefore overgrazing of plants (Aresta, 
Cotugno, Massari, & Zambonin, 2017). Depending on the structure of the phytoestrogen, 
they are classified into a number of different groups and include lignans, found in flaxseed 
and wheat, and isoflavones which are found in high concentrations in soybeans (Poluzzi et 
al., 2014; Upmalis et al., 2000). Some phytohormones are known to interact with the α and 
β estrogen receptors in the human body (Sirotkin & Harrath, 2014) and trigger a biological 
response similar to that caused by natural estrogen (Rafii, 2015). The reason for this is due 
to the remarkably structural similarity between phytoestrogens and estrogen. Isoflavones 
act as natural selective estrogen receptor modulators by acting as agonists for estrogen 
receptors on bone and antagonists for estrogen receptors on breast tissue (Wang et al., 
1996). These properties have made isoflavone supplementation an attractive alternative to 
estrogen therapy for post-menopausal women. However, isoflavones are, at best, currently 
considered only as a second-line therapy after HRT (Brown, Josse, & Canada, 2002). 
  The present study is an extension of a previous study (Chilibeck et al., 2013) on 
the effects of combining an isofalvone supplement with exercise, and with isoflavone and 
exercise alone on bone mineral properties. In the Chilibeck et al., (2013) study, women 
were randomly placed into four different groups: exercise only, isoflavone only, combined 
exercise and isoflavone, and control (no exercise or isoflavone). It was hypothesized that 
the combined isoflavone and exercise training would have a positive and additive effect on 
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BMD of the proximal femur and a smaller effect on the lumbar spine. Chilibeck et al., 
(2013) reported, however, a negative outcome on bone mineral properties when isoflavone 
was combined with exercise training for two years (i.e. there was a negative interaction 
when isoflavone supplementation was combined with exercise), while the isoflavone or 
exercise alone improved bone mineral properties. The main aim of the present study is to 
assess the effect of an additional year of exercise training with cessation of isoflavone 
therapy. To the author’s knowledge, this is the first ever research study which evaluates, 
over three years, the effects of exercise in women who are confirmed to be postmenopausal 
and are not undergoing any medicinal therapy. Eighty-six out of 298 original participants 
volunteered for the additional year of exercise training, or be assessed for another year if 
they were not originally assigned to the exercise groups. We hypothesized that there would 
be an improvement in bone mineral properties, bone geometry, body composition, and 
muscle strength among those who exercised over an additional year as well as in the 
combined therapy group after cessation of isoflavone supplementation.   
2. Literature Review 
2.1. Post-menopausal Bone Loss  
 The onset of bone loss in healthy women occurs at about two years before the last 
menses and accelerates to a significantly higher rate four to five years after menopause 
(Recker, 2011) (Figure2). In early menopause, the main bone loss occurs in the trabecular 
bone and is thought to be caused by estrogen deficiency (Lerner, 2006). As previously 
noted, bone loss is thought to be due to increased activity by osteoclasts whose primary 
function is to dissolve and resorb bone. When young, the osteoblasts and osteoclasts work 
synchronously with osteoblasts dominating thus resulting in a net bone gain. However, due 
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to aging and reduction in estrogen, concomitant with reduced mobility, the proliferation of 
osteoblasts becomes reduced thus resulting in bone resorption dominating (Klein-Nulend 
et al., 2012; Klein-Nulend et al., 2015; Lerner, 2006).  This phase of post-menopausal bone 
loss continues for four to eight years and is followed by the second phase with continuation 
of trabecular bone and cortical bone loss. Menopause by itself is not a partition so that prior 
to it there is no bone loss. In fact, women begin losing bone around the age of 35 but this 
accelerates after menopause (Josse et al., 1996).  This is likely due to a decrease in estrogen 
levels, which is considered to be the leading cause of bone loss and osteoporosis in 
postmenopausal women. With the decline in estrogen, the bone remodelling process 
reconfigures and results in a high rate of bone loss (Riggs & Melton, 1992). Although 
hormone replacement therapy (HRT) was at one time considered to be the first line of 
management to lessen bone loss and therefore prevent bone fractures (Torgerson & Bell-
Syer, 2001), it was later found that HRT increased the risks for invasive breast cancer and 
cardiovascular diseases (CVD), and the risks outweighed the benefits (Poluzzi et al., 2014; 
Rossouw et al., 2002). Given these associated risks, it was recommended that HRT should 
not be undertaken (Writing Group for the Women's Health Initiative Investigators, 2002). 
Due to these side effects, many women are hesitant to start HRT in order to alleviate the 
symptoms of osteoporosis and many women have turned away from prescription drugs and 
towards alternative remedies (Poluzzi et al., 2014).  
 
2.2. Isoflavones. 
 Phytoestrogens, including isoflavones, are naturally produced plant compounds 
which are non-steroidal, structurally similar to estradiol and have been shown to compete 
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with estradiol for estrogen receptor sites in the human body (Shutt & Cox, 1972; Verdeal, 
Brown, Richardson, & Ryan, 1980). They may act as agonists with respect to bone and 
antagonists with respect to uterine and breast tissue (Mueller & Korach, 2001). 
Furthermore, they have a higher affinity to the estrogen receptors specific to osteoblasts 
and a lower affinity for the estrogen receptors that are found predominantly in uterine tissue 
(Picherit et al., 2001). Given these characteristics of isoflavones, and the negative side 
effects of estrogen HRT, phytoestrogens have been considered as a therapeutic option for 
osteoporosis (Komm & Chines, 2012). In contrast to estrogen, isoflavones do not increase 
the incidence of breast cancer and in fact have been associated with a decreased risk for 
breast cancer (Ingram, Sanders, Kolybaba, & Lopez, 1997; Murkies et al., 2000; Torres-
Sànchez, López--Carrillo, Ló--Cervantes, Rueda-Neria, & Wolff, 2000). Isoflavones, 
therefore, may act as natural selective estrogen receptor modulators by acting as agonists 
for estrogen receptors on bone and thereby stimulate osteoblast activities (Wang et al., 
1996). Although the benefits of isoflavone supplementation may be attractive and 
promising, a number of recent publications and meta-analyses have critically examined if 
soy isoflavones are effective in treating or stabilising postmenopausal bone loss (Lanou, 
2011; Taku et al., 2010). The authors of the aforementioned studies have concluded that 
there is insufficient evidence to recommend the use of isoflavones for bone health. In fact, 
there are many factors, such as menopausal status, supplement type, isoflavone dose and 
intervention duration, which still need to be studied in order to fully understand if 
isoflavones are efficacious when it comes to bone health in postmenopausal women (Wei, 
Liu, Chen, & Chen, 2012). 
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2.3. Exercise and BMD 
 As noted previously, osteocytes are sensitive to and stimulated by mechanical stress 
on bones which is exerted during movement and physical exercise and these can, by 
stimulating bone formation, help to reduce the risk for fractures in postmenopausal women 
(Kemmler, Bebenek, Kohl, & von Stengel, 2015). Exercise programs, through increasing 
dynamic balance, reflexes and coordination, can help to reduce falls and all fracture risks 
(Gillespie et al., 2012), fall impacts (Groen, Smulders, De Kam, Duysens, & Weerdesteyn, 
2010), and increase bone strength (Marques, Mota, & Carvalho, 2012). Exercise training 
has been known to improve BMD and neuromuscular function as well as reduces the 
number and severity of fractures in older adults. Furthermore, exercise contributes to a 
decrease in age-related bone loss as well as in promoting faster recovery if there has been 
a fracture (Kemmler & von Stengel, 2014). Indeed, exercise is a highly effective 
prescription for improving or stabilizing BMD, reducing falls and fracture risk, and in the 
recovery of osteoporotic fracture in postmenopausal women (Kemmler et al., 2015).  
 The most recent systematic review of exercise and BMD in postmenopausal women 
showed that bones' adaptive response to exercise is significantly more favorable when 
exercising >2–4 times a week as compared to exercising <1.5–2 times per week (Kemmler 
& von Stengel, 2014). In addition, it has also been noted that exercising six hours per week 
is needed to maintained BMD (Karlsson, Magnusson, Karlsson, & Seeman, 2001). 
Moderate-impact aerobic activity (e.g., walking, jogging, skipping, hopping) has long-
term benefits in that it helps to prevent osteoporosis in postmenopausal women (Cussler 
et al., 2005). Moreover, mechanical vibration has also shown to be beneficial on bone 
microarchitecture, bone density and strength, as well as in elevating physical function and 
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mobility (Moreira et al., 2014). As one gets older, bone turnover (e.g. bone formation and 
resorption) slows but with exercise, the BMD increases by about 1-2% per year (Bonaiuti 
et al., 2002). However, a 5% increase in BMD is necessary for a clinically significant 
reduction in the risk of a fracture (Guyatt et al., 2002).  
 While Chilibeck et al., (2013) studied the effects of isoflavone and exercise on 
BMD, no study has investigated the effects of a resistance-training program greater than 
two years in duration on BMD in postmenopausal women (Howe et al., 2011). The present 
study is especially relevant as a recent meta-analysis reported favorable outcomes of 
exercise on nearly almost all fracture risks (Kemmler, Haberle, & von Stengel, 2013). 
Furthermore, an exercise regime is currently considered to be a first line of treatment in 
stabilizing and preventing osteoporosis in postmenopausal women (Papaioannou et al., 
2010). 
 
2.4. Exercise and Bone Geometry 
 Most studies which measure the effects of exercise on bone density in 
postmenopausal women utilize aBMD as their primary indicator. Some studies have noted 
that in some exercise studies, aBMD does not vary and that there were no changes in bone 
mass. This is somewhat misleading as a recent review of aBMD and exercise noted that 
aBMD may not fully capture the benefits of exercise on bone (Harding & Beck, 2017). The 
primary reason for this is that bone is three dimensional while DXA scans, which are the 
primary mode of measurements for bone density, provide only planar data. Furthermore, 
two dimensional data can lead to further inaccuracies because the relationship between 
bone area and volume is non-linear thereby leading to underestimation as to the effects of 
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exercise. This means that studies in postmenopausal women and exercise are overlooking 
bone morphology and geometry, which requires a volumetric measurement of BMD in 
g/cm3 and would be more representative and accurate a criteria as compared to areal BMD 
(g/cm2) (Harding & Beck, 2017). This means that exercise is having an effect on bone 
morpohology and geometry but the DXA is unable to capture it. 
 In another review of the literature, but with a focus on studies which measured the 
effects of exercise on both bone mass and volume using DXA and peripheral quantitative 
computed tomography (pQCT), the authors reported that in nearly all of the studies 
analyzed there were positive changes in bone mass and geometry as measured by the latter 
even though DXA data showed little to no change (Hamilton, Swan, & Jamal, 2010). 
Although pQCT has its limitations, one being the inability to measure sites which are more 
clinically relevant to fractures such as the hips and the lumbar spine, it has its benefits in 
that it can measure bone size and shape, and volume. The authors also pointed out that in 
postmenopausal women, exercise effects were largely seen in cortical rather than the 
trabecular portions of the bones. This suggests that the instruments used to scan and collect 
data may be limited in some way and the full scope of changes may have been 
underestimated. Furthermore, it was noted that bone mass and geometric changes were 
highly dependent on the type of exercise the participants engaged in. Generally, the more 
vigorous the physical activity, the greater the benefits of exercise so that exercises which 
required running, bounding and jumping were much more beneficial than simple weight 
bearing exercises or dancing (Hamilton et al., 2010). Therefore, it has been shown that 
exercise does have a positive effect on bone mass and geometry but that DXA scans may 
be unable to measure the changes.  
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2.5. Exercise, Dynamic Balance and Fracture Prevention 
 As noted previously, as people age there is a commensurate decrease in their muscle 
mass and mobility, and this negatively affects BMD due to a lack of mechanical stress. 
Furthermore, there is a positive correlation between fracture rates and age so that the 
elderly are more likely to have all-type fractures as compared to people who are younger 
(Hopkins et al., 2016). Given these scenarios, research has indicated that one of the best 
interventions to prevent falls, and injuries and fractures resulting from falls, is exercise. 
The latter strengthens the muscles, increases balance and coordination, and the speed and 
effectiveness of reflexes to mitigate the injurious effects of falls, such as extending an arm 
to grab an object or to soften an impact. A recent meta-analysis examined 17 exercise trials 
which involved 4305 participants with a mean age of 76.7, and with 77 percent of the 
participants being women (El-Khoury, Cassou, Charles, & Dargent-Molina, 2013). The 
authors found that in the exercise group there was a 37 percent reduction in all injurious 
falls, 43 percent reduction in falls which led to severe injuries, and a decrease of 61% for 
falls which resulted in fractures.  
 Similarly, another meta-analysis consisting of a comparison of 88 trials comprised 
of 19,478 participants who were 65 years of age or older found that there was a 21% 
decrease in falls in people who exercised more than three hours per week as compared to 
those who did not exercise (Sherrington et al., 2016). Moreover, these reductions extended 
to people who had Parkinson’s disease as well as those who were cognitively impaired. In 
another recent study, the authors examined the effects of exercise on 70 to 80 years old 
women who had fallen previously (Patil et al., 2015). The authors found that although there 
was no decrease in the number of falls between the exercise and non-exercise group, the 
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women who exercised were half as likely to need medical attention as those who did not 
exercise. These studies show that exercise can significantly help to prevent falls and also 
reduce the severity of injuries and fractures if one falls.  
 However, the above data should be treated with caution as there have been reports 
that the correlation between BMD and fracture risk is not simple and that the primary 
reasons for fractures may be other than osteoporosis. In a population-based random sample 
study on postmenopausal women over the age of 60, the authors conducted aBMD scans 
over a number of years (Pasco et al., 2006). The authors reported that in scans conducted, 
with a median time of 5.6 years between scans, 37.6%, 48.0%, and 14.5% of the women 
showed normal, osteopenic (e.g. less than one standard deviation below peak bone mass), 
and osteoporotic total hip aBMD, respectively. At the study’s end, 73.1% (56.5% 
osteopenic and 16.6% with normal aBMD) of all low trauma fractures were reported by 
women without osteoporosis. Moreover, the authors noted that of the women with 
osteopenia who reported a low level fracture, the chance of them not having another 
fracture over the next five years was lower than women with osteoporosis and no fractures 
(Pasco et al., 2006). This suggests that the loss of coordination and mobility may play a 
greater risk for fractures, or that women who know they have osteoporosis are more likely 
to be more cautious in their activities as compared to women who are not diagnosed as 
having osteoporosis.  
 
2.6. Previous Study Results.  
The hypothesis of the Chilibeck et al., (2013) study, of which the present study is a 
continuation, was that isoflavone supplementation (165 mg total isoflavone d-1 or 105 mg 
aglycone equivalent d-1) and exercise training would be additive and increase lumbar spine 
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and proximal femur BMD as compared to the controls (no isoflavone and no exercise), 
those who only exercised (no isoflavone), and those who only took isoflavone (no exercise). 
Contrary to the hypothesis, it was found that in the exercise plus isoflavone group, similar 
to that of the control group, there was a decrease in total hip BMD. Furthermore, there was 
a deterioration in BMD at the narrow neck and femoral shaft regions of the proximal femur 
in the combined exercise plus isoflavone group compared to the exercise-only group that 
approached statistical significance (p = 0.055). In the exercise alone and the isoflavone by 
itself groups, on the other hand, total hip BMD was maintained. These findings suggested 
that there was a negative interaction between combining exercise and isoflavone 
supplements. The authors hypothesized that the reason why the therapy combination led to 
a decrease in total hip BMD was due to the higher affinity of isoflavone to interact with 
the β-estrogen receptor rather than the α-estrogen receptor on bone. The α receptor is 
known to activate osteoblast activity (Damien, Price, & Lanyon, 2000) thereby promoting 
bone formation, whereas activation of the β receptor dampens or blocks the positive effects 
of mechanical stress on bone (Saxon & Turner, 2005). However, the reason as to why the 
combination therapy resulted in greater total hip BMD loss is likely to be more complex 
than receptor affinity. This is because if it was simply due to isoflavone blocking the 
stimulating mechanical stress on bone, the isoflavone without exercise group should have 
lost more BMD than both the control and the combination therapy group.  
Nonetheless, besides the above, Chilibeck et al., (2013) also found, as could be 
expected, that there was a positive effect on dynamic balance and leg strength in the 
exercise groups compared to non-exercise groups, with a greater increase in leg strength 
also apparent in isoflavone groups compared to non-isoflavone groups. The stimulating 
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effect of isoflavone on leg strength was thought to be due to the fact that there are estrogen 
receptors in muscle and the isoflavone may have led to increased muscle mass which then 
translated into greater leg strength.  
 
3. Research Aim and Hypothesis 
3.1 Primary Aim 
 The primary objective of this study was to investigate the BMD at lumbar spine 
and proximal femur in postmenopausal women after cessation of isoflavone therapy, but 
with continuation of exercise training. 
3.2 Primary Hypothesis 
 It was hypothesized that an additional year of exercise training after cessation of 
isoflavone therapy, or continued exercise training for an additional year in postmenopausal 
women who never received isoflavone in the first study, would maintain lumbar spine and 
proximal femur BMD as compared to loss in the control groups who did not exercise. 
Furthermore, it was also hypothesized that the group that previously received the exercise 
+ isoflavones treatment would have the greatest increase in bone measures since the 
inhibitory effect of isoflavones was removed for the third year. 
 
3.3 Secondary Aim 
 The secondary objective was to assess the effects of exercise on bone geometry at 
the proximal femur. 
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3.4 Secondary Hypothesis  
 An additional year of exercise training after cessation of isoflavone therapy, or 
continued exercise training for an additional year in postmenopausal women who never 
received isoflavone in the first study, would be effective in improving bone geometry as 
compared to the control group who did not exercise. Moreover, it was further hypothesized 
that the group that previously received the exercise + isoflavone treatment would have the 
greatest increase in bone geometry as compared to the other groups since the inhibitory 
effect of isoflavones was removed for the third year. 
3.5 Tertiary Aim 
The tertiary objective was to assess the effects of exercise on body composition, 
anthropometry, balance, walking speed, and strength (bench press and hack squat strength). 
3.6 Tertiary Hypothesis 
 An additional year of exercise training after cessation of isoflavone therapy, or 
continued exercise training for an additional year in postmenopausal women who never 
received isoflavone in the first study, would be effective in improving body composition, 
anthropometry, balance, walking speed, and strength (bench press and hack squat strength).   
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4. Methods  
4.1. Participants  
4.1.1. Number of Participants and Group Allocation 
 
 A total of 86 participants completed the additional year of exercise training or 
were part of the control group which did no training, after complete cessation of soy 
isoflavone supplementation. Participants were divided into four groups (Figure 3) as in 
the previous study: exercise, isoflavone, exercise + isoflavone, and control group. The 
isoflavone and control groups did stretching exercise at home as an exercise placebo. The 
other two groups attended the exercise training for an additional year with supervision. 
All participants were postmenopausal, as verified by determining levels of follicle 
stimulating hormone and luteinizing hormone at the start of the original study (Chilibeck 
et al., 2013).  
4.1.2. Inclusion Criteria  
 Postmenopausal women  
4.1.3. Exclusion Criteria for the Chilibeck et al., (2013) study were the following: 
  Previous fragility fractures (defined as fractures resulting from minimal trauma); 
having taken bisphosphonates, HRT, selective estrogen receptor modulators such as 
Rolaxofene or calcitonin within the previous 12 months before the original study; currently 
taking corticosteroids; Crohn’s disease; Cushing’s disease; kidney disease, allergy to soy; 
severe osteoarthritis; currently involved in vigorous exercise training as defined by jogging 
or resistance training for more than 20 minutes per session, more than twice per week; 
planning to travel outside of Saskatoon for an extended period during the study; 
osteoporosis (lumbar spine or proximal femur aBMD 2.5 SD below the young adult mean 
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(i.e. T-score of –2.5 or lower); current or previous breast cancer; and current or previous 
endometrial cancer.  
 All exclusion criteria were determined by questionnaire except for osteoporosis, 
breast cancer, and endometrial cancer, which were evaluated by bone densitometry, 
mammography, and ultrasound, respectively. Participants who developed osteoporosis or 
started taking medications for low aBMD during the study were excluded from the study. 
This was required for ethical reasons as women who developed osteoporosis were referred 
to their family physicians for treatment. Participants were recruited into the extension study 
by asking them to participate in a one year extension of the previous study, but with 
cessation of the isoflavone supplement. A new consent form was signed for the extension 
study. 
 
Figure 3: Extension study participant groups  
Group1-Ex= Exercise training (combined weight training and walking) plus previously 
received isoflavone placebo; 
Group2-past Iso= exercise training placebo (flexibility program) plus previously received 
isoflavone therapy;  
Group3-past Iso+Ex= exercise training; and previously received isoflavone;  
Group4-control= exercise training placebo plus isoflavone placebo.  
 
86 participants
Group1 -Ex
n = 28
Group2-past Iso
n = 18
Group3 (past 
Iso+Ex) 
n = 26
Group4-Control
n = 14
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4.1.4 Subject Withdrawal Criteria 
A participant who developed any of the conditions outlined in the exclusion criteria, 
or who had a serious adverse event likely related to the intervention, was removed from 
the study. 
An attempt was made to collect all follow-up data on the participants after they 
were removed so data could be analyzed as “intent to treat”. 
4.2. Exercise Protocol  
The exercise training intervention was adopted from a previous study and consisted 
of weight training combined with walking (Chilibeck, 2005). The exercise training placebo 
consisted of a home-based flexibility program, which was found to have no effect on 
aBMD. Exercise involved strength (resistance, weight) training twice a week and brisk 
walking four times per week. The strength training and walking were combined two days 
per week, at which time exercise sessions were fully supervised. On two other days of the 
week, subjects were required to perform walking exercise on their own. Compliance to the 
exercise program was monitored by activity logs.  
Exercises done during strength training included: 
 hack squat,  
 hip abduction - on a multi-hip machine,  
 hip adduction - on a multi-hip machine, 
 hip flexion - on a multi-hip machine, 
 hip extension - on a multi-hip machine,  
 hamstring curl,  
 quadriceps (knee) extension,  
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 back extension,  
 abdomen flexion,  
 bench press,  
 lat-pull down,  
 shoulder press 
 Biceps curl, and triceps extension (presses).  
 
 Two sets of 8 repetitions for each exercise were done at intensities corresponding 
to approximately 80% of 1 repetition maximum (1RM). The walking program involved 
20-30 minutes of brisk walking per session at an intensity corresponding to 70% of age- 
predicted maximal heart rate (220-age).  Intensity and duration of exercise was increased 
progressively on an individual basis. Pedometers were given to the women to track walking 
distance and to encourage compliance. 
The exercise placebo participants were given a home-based flexibility program that 
involved stretching exercises for all of the major muscle groups, requiring 20-30 minutes 
of stretching four days per week. The exercise placebo participants were telephoned 
periodically to assess compliance to the flexibility program.  
The duration of the extension study was one year. 
 
4.3. Measurements  
 All of the measurements and protocols were adapted from Chilibeck (2005).  
4.3.1. Primary Outcomes 
The primary outcome was to measure the change in proximal femur aBMD at 12, 24, and 
36 months. 
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4.3.2. Secondary Outcomes 
The secondary outcomes included: 
 Lumbar spine aBMD  
 Whole body aBMD 
 Bone geometry at the proximal femur (bone cross-sectional area (CSA), 
cross-sectional moment of inertia (CSMI), and section modulus (Z), at the 
narrow part of the femoral neck, the intertrochanteric region of the hip, and 
the shaft of the femur. 
 Body composition by densitometry (i.e. collected at the same time as whole-
body aBMD) 
 Anthropometry (waist circumference, body mass, height, and body mass 
index (BMI)  
 Balance 
 Walking speed 
 Bench press and hack squat strength 
Changes in all secondary measures were assessed at 36 months, or one year after cessation 
of the two years of the Chilibeck et al., (2013) study.  
4.4. Methods and Measurements 
            All of the methods and measurement protocols were adapted from Chilibeck  
et al., (2013). 
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  Figure 4: DXA machine, with proximal femur and lumbar spine scan 
  
 Body composition was assessed with dual-energy X-ray absorptiometry (DXA) 
(Figure4). aBMD of the whole body, lumbar spine (L1–L4 vertebrae), and proximal femur 
(including the femoral neck, trochanter, Ward’s, and total hip) were measured by DXA in 
array mode (QDR Discovery Wi; Hologic, Inc., Bedford, MD, USA) using QDR software 
for Windows XP (QDR Discovery, Hologic, Inc. Marlborough, MA, USA). The 
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coefficients of variation for these measures were 0.5% for the whole body, 0.7% for the 
lumbar spine, and 1.0% for the proximal femur. Lean tissue and fat mass were assessed 
from the whole- body scans and the coefficients of variation for these measurements were 
0.5%, and 3%, respectively. Hip structural analysis (HSA), adapted from Beck et al., 
(2011), was used to assess structural characteristics of three regions of the proximal femur 
from the DXA scans: the narrow neck region, which is located across the narrowest 
segment of the femoral neck; the intertrochanteric region along the bisector of the neck- 
shaft angle; and the femoral shaft, which is located 2 cm distal to the midpoint of the lesser 
trochanter (Beck et al., 2011). For each region, the distribution of the bone mass across the 
bone is extracted, then CSA, which is equivalent to cortical area of CSMI, and aBMD 
(grams of bone divided by bone area) were measured. Like BMC, CSA measures the 
amount of bone within the cross-section but expresses the quantity in terms of cortical 
equivalent surface area (important for axial bone strength) rather than mineral mass. The 
coefficients of variation for narrow neck, intertrochanteric, and femoral shaft regions, 
respectively, were as follows: aBMD (1.7%, 1.3%, and 1.3%); subperiosteal width SPW 
(5.3%, 1.8%, and 1.2%); CSA (2.6%, 2.2%, and 1.8%); CSMI (7.2%, 4.3%, and 3.7%); Z 
(3.5%, 3.4%, and 2.1%). aBMD and geometric measurements of multiple areas of the 
proximal femur were included as outcomes because each has been associated with fracture 
risk (LaCroix et al., 2010; Wu, Wang, & Shyu, 2011).  
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Figure 5: Hack squat, bench press, and dynamic balance test. 
 
 Strength in the lower body was assessed by determining the 1- RM during the hack 
squat whereas upper body strength was determined by the 1-RM during the bench press 
(Chrusch, Chilibeck, Chad, Davison, & Burke, 2001)(Figure5).  Dynamic balance was 
measured as time taken to perform backward tandem walking (i.e., toe to heel) over a 
distance of 6 m on a board that was 10 cm in width and raised about 4 cm off of the ground. 
Number of errors (i.e. number of times the participant stepped off the walking board) 
during the test was also recorded as a measure of dynamic balance (Figure5). This test is 
sensitive to the effects of exercise training (Nelson et al., 1994). Walking speed was 
assessed by timing walking over an 80 m course at a fast pace (Himann, Cunningham, 
Rechnitzer, & Paterson, 1988). The coefficients of variation for squat strength, bench press 
strength, dynamic balance (backward tandem walking time), and walking time over 80 m, 
were 31.3%, 8.2%, 19.3%, and 4.5%, respectively.  
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4.5. Participant numbers 
 A total sample size of 86 participants was based on volunteers from a previous 
study agreeing to complete an additional year of the research trial. Participants continued 
in the 4 groups to which they were originally randomized, except that the groups assigned 
to take isoflavone supplement stopped taking the supplement: 
Group 1 (n = 28)- exercise training (combined weight training and walking)  
Group 2 (n = 18)- exercise training placebo (flexibility program) plus previously received 
isoflavone (94 mg aglycone equivalent d-1 (157 mg total isoflavone d-1)); 
Group 3 (n = 26) - exercise training; and previously received isoflavone. 
Group 4 (n = 14) - exercise training placebo plus isoflavone placebo.  
 
4.6. Data Analysis  
 Statistical analysis of change in aBMD, bone geometry, body compensation, 
anthropometry and strength between the groups over a 3-year period were assessed using 
IBM’s Statistical Package for the Social Science (SPSS). The statistical analysis utilized a 
3-factor ANOVA with a between-groups factor for exercise, a between-groups factor for 
isoflavone (i.e. removal of isoflavone) and a within-groups factor for time (baseline, 1 year, 
2 years, 3 years). A p < 0.05 was accepted as significant. If there was statistically significant 
group × time interaction, Tukey's honestly significant difference (HSD) post hoc test was 
run on the data. 
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5. Results 
 Baseline data for the participants who took part in the extension study are presented 
below in Table 1. The total number of participants who agreed to be a part of the extended 
third year study was 86. However, the bone geometry data consisted of 68 participants as 
some scans were unable to be analyzed due to poor positioning during the scans.    
 
Table 1. Baseline Data 
 
 
Sample 
Size  
Mean Std. 
Deviation 
Age (y) Exercise 28 57  
 
7 
 
Past-Isoflavone 18 60 
 
6  
Exercise + Past-
Isoflavone 
26 58 6  
Control  14 63   
 
10  
Total 86 59  
 
7   
 
Weight (kg) Exercise 28 68 10 
Past-Isoflavone 18 73  11 
Exercise + Past-
Isoflavone 
26 69 11 
Control 14 66 10  
Total 86 69 10  
Height (cm) Exercise 28 163 5  
Past-Isoflavone 18 164 7 
Exercise + Past-
Isoflavone 
26 163 5 
Control  14 163 5 
Total 86 163 5  
 
 
Waist Girth (cm) 
Exercise 28 82  10 
Past-Isoflavone 18 87  12 
Exercise + Past-
Isoflavone 
26 85  11 
Control  14 83  10 
Total 86 84  11 
Lumbar aBMD  Exercise 28 0.94 0.09 
 28 
(g cm-2) Past-Isoflavone 18 0.95 0.14 
Exercise + Past-
Isoflavone 
26 0.96 0.11 
Control  14 0.97 0.10 
Total 86 0.95 0.11 
Femoral Neck 
aBMD (g cm-2) 
Exercise 28 0.72 0.07 
Past-Isoflavone 18 0.77 0.10 
Exercise + Past-
Isoflavone 
26 0.74 0.08 
Control  14 0.74 0.08 
Total 86 0.74 0.08 
Total Hip aBMD  
(g cm-2) 
Exercise 28 0.88 0.09 
Past-Isoflavone 18 0.91 0.10 
Exercise + Past-
Isoflavone 
26 0.89 0.10 
Control  14 0.89 0.09 
Total 86 0.89 0.09 
Trochanter aBMD 
(g cm-2) 
Exercise 28 0.67 0.08 
Past-Isoflavone 18 0.70 0.08 
Exercise + Past-
Isoflavone 
26 0.69 0.08 
Control  14 0.67 0.06 
Total 86 0.68 0.08 
Intertrochanteric 
CSMI (cm4) 
Exercise 20 12.30 3.13 
Past-Isoflavone 14 13.60 2.95 
Exercise + Past-
Isoflavone 
19 13.03 2.30 
Control  14 12.38 2.10 
Total 67 12.83 2.62 
Shaft CSMI (cm4) Exercise 20 3.13 0.56 
Past-Isoflavone 14 3.64 0.99 
Exercise + Past-
Isoflavone 
19 3.59 0.60 
Control  14 3.49 0.60 
Total 67 3.47 0.69 
Narrow Neck 
CSMI (cm4) 
Exercise 20 2.09 0.47 
Past-Isoflavone 14 2.39 0.60 
Exercise + Past-
Isoflavone 
19 2.27 0.43 
Control  14 2.04 0.34 
Total 67 2.20 0.46 
Intertrochanteric 
Section Modulus 
(cm3) 
Exercise 20 4.20 0.84 
Past-Isoflavone 14 4.46 0.77 
Exercise + Past-
Isoflavone 
19 4.42 0.69 
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Control  14 4.16 0.61 
Total 67 4.31 0.73 
Shaft Section 
Modulus (cm3) 
Exercise 20 2.17 0.32 
Past-Isoflavone 14 2.39 0.44 
Exercise + Past-
Isoflavone 
19 2.41 0.31 
Control  14 2.35 0.30 
Total 67 2.33 0.34 
Narrow Neck 
Section Modulus 
(cm3) 
Exercise 20 1.30 0.21 
Past-Isoflavone 14 1.38 0.27 
Exercise + Past-
Isoflavone 
19 1.34 0.20 
Control  14 1.25 0.18 
Total 67 1.32 0.21 
Intertrochanteric 
Cross-Sectional 
Area (cm2) 
Exercise 20 4.70 0.68 
Past-Isoflavone 14 4.88 0.64 
Exercise + Past-
Isoflavone 
 
19 
4.91 0.71 
Control  14 4.82 0.73 
Total 67 4.83 0.69 
Shaft Cross 
Sectional Area 
(cm2) 
Exercise 20 4.18 0.57 
Past-Isoflavone 14 4.48 0.61 
Exercise + Past-
Isoflavone 
 
19 
4.51 0.51 
Control  14 4.44 0.51 
Total 67 4.40 0.55 
Narrow Neck Cross 
Sectional Area 
(cm2) 
Exercise 20 2.67 0.35 
Past-Isoflavone 14 2.88 0.47 
Exercise + Past-
Isoflavone 
 
19 
2.85 0.37 
Control  14 2.72 0.29 
Total 67 2.78 0.37 
Intertrochanteric 
aBMD (g cm-2) 
Exercise 20 0.95 0.13 
Past-Isoflavone 14 0.96 0.14 
Exercise + Past-
Isoflavone 
19 0.98 0.14 
Control  14 0.96 0.14 
Total 67 0.96 0.14 
Shaft aBMD  
(g cm-2) 
Exercise 20 1.54 0.21 
Past-Isoflavone 14 1.59 0.21 
Exercise + Past-
Isoflavone 
19 1.63 0.21 
Control  14 1.60 0.16 
Total 67 1.59 0.20 
Exercise 20 0.91 0.12 
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Narrow Neck 
aBMD (g cm-2) 
Past-Isoflavone 14 0.96 0.15 
Exercise + Past-
Isoflavone 
19 0.96 0.12 
Control  14 0.95 0.12 
Total 67 0.94 0.13 
Whole Body Lean 
Mass (g) 
Exercise 28  
25 
 
5.32 
Past-Isoflavone 18 29 7.04 
Exercise + Past-
Isoflavone 
26 27 7.25 
Control  14 25 6.95 
Total 86 27 6.64 
Whole Body aBMD 
(g cm-2) 
Exercise 28 12 3.70 
Past-Isoflavone 18 14 4.71 
Exercise + Past-
Isoflavone 
26 13  4.80 
Control  14 12 4.21 
Total 86 13 4.36 
Whole Body Fat 
Mass (kg) 
 
Exercise 
 
28 
57  34.92 
Past-Isoflavone 18 56  49.04 
Exercise + Past-
Isoflavone 
26 59  32.65 
Control  14 32 35.08 
Total 86 51  37.92 
Trunk Fat Mass 
(kg) 
Exercise 28 65 22.65 
Past-Isoflavone 18 68 21.23 
Exercise + Past-
Isoflavone 
26 70  22.91 
Control  14 56 29.67 
Total 86 65 24.11 
Hack Squat (kg) Exercise 28  
25 
 
5.32 
Past-Isoflavone 18 29 7.04 
Exercise + Past-
Isoflavone 
26 27 7.25 
Control  14 25  6.95 
Total 86 27 6.64 
Chest Press (kg) Exercise 28 12 3.70 
Past-Isoflavone 18 14  4.71 
Exercise + Past-
Isoflavone 
26 13  4.80 
Control  14 12 4.21 
Total 86 13 4.36 
Balance Time (s) Exercise 28 37 16.22 
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aBMD = Areal bone mineral density  
CSMI = cross-sectional moment of inertia 
 
 
5.1 Bone Outcomes 
 For total hip and lumbar spine aBMD there was an exercise group x time interaction 
(p  0.05).  In the exercise groups, total hip aBMD decreased from baseline to year 2 and 
year 3, and lumbar spine aBMD decreased from baseline to year 3 (Table 2) (Figures 6 and 
7). There were time main effects for aBMD at the femoral neck, trochanter, and whole 
body, with aBMD decreasing over time (p<0.01) (Table2). For most geometric measures 
(i.e. CSMI, section modulus, CSA, superiosteal width) there were time main effects 
(p<0.05) with measures increasing over time (Table2). The exceptions were an exercise 
group x time interaction for CSMI of the femoral shaft (p<0.05) (Figure 8) and an 
isoflavone group x time interaction for superiosteal width of the femoral shaft (p<0.05) 
(Figure 9). Post-hoc analysis showed that both the exercise groups and non-exercise groups 
increased femoral shaft CSMI from baseline to year 3; the exercise group x time interaction 
Past-Isoflavone 18 45 14.36 
Exercise + Past-
Isoflavone 
26 43  13.73 
Control  14 48  14.79 
Total 86 43  14.77 
Balance Errors Exercise 28 2  2.37 
Past-Isoflavone 18 3 2.69 
Exercise + Past-
Isoflavone 
26 2 2.21 
Control  14 2 1.32 
Total 86 2 2.15 
80m Walk Test 
Fast (s) 
Exercise 28 53 6.01 
Past-Isoflavone 18 52  6.26 
Exercise + Past-
Isoflavone 
26 52 6.39 
Control  14 55  7.01 
Total 86 53 6.42 
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was due to a greater increase in the non-exercise groups. Post-hoc analyses showed no 
difference over time for any groups for femoral shaft superiosteal width; the isoflavone 
group x time interaction is therefore difficult to interpret.  
  
5.2. Balance, Exercise, Anthropometric tests, and Body Composition 
 There were no changes in lean tissue mass between the groups. There were exercise 
group x time interactions for total body fat mass, percent fat, and trunk fat mass (p<0.05) 
(Figures 10, 11, 12) (Table 3), with all decreasing over time in the exercise groups but with 
no change in the non-exercise groups. 
 There were exercise group x isoflavone group x time interactions for body weight 
and waist girth (p<0.05) (Figures 13, 14). Body weight decreased in the exercise + past 
isoflavone group from baseline to years 2 and 3 (p<0.01) with no changes in other groups. 
The post-hoc of the 3-way interaction for waist girth showed no differences over time 
within groups, but again it appeared this interaction was due to a decrease in the exercise 
+ past isoflavone group with no change in the other groups. 
 As could be expected, the exercise groups improved significantly (p < 0.01) than 
the non-exercise groups in squat strength and chest press (Figures 15 and 16). There were 
time main effects (p<0.01) for walking time and balance time with both decreasing over 
time (indicating an improvement in performance across groups) (Table4). There were no 
significant changes in balance errors. 
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 Figure 6: Decreased total hip bone mineral density (aBMD) in the exercise 
groups (p  0.05). 
*= (p  0.05) Versus Baseline. 
 
 
 
 Figure 7: Decreased lumbar spine bone mineral density (aBMD) in exercise 
groups (p  0.05). 
*= (p  0.05) Versus Baseline. 
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 Figure 8: Exercise group x time interaction for cross-sectional moment of inertia 
(CSMI) at the femoral shaft (p  0.05) 
 
 
 
 
 
 
 
 
Figure 9: Isoflavone group × time interaction for superiosteal width of the femoral shaft 
(p  0.05) 
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Figure 10: Decreased whole body fat mass in exercise groups. 
*= (p  0.05) Versus Baseline. 
 
 
 
 
 
 
 
Figure 11: Decreased percent fat in exercise groups. 
*= (p  0.05) Versus Baseline. 
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Figure 12: Decreased trunk fat mass in exercise groups (p  0.05). 
*= (p  0.05) Versus Baseline. 
 
 
 
 
 
 
Figure 13: Body weight decrease in the exercise + past isoflavone groups (p  0.05). 
*= (p  0.05) Versus Baseline. 
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Figure 14: Exercise group x isoflavone group x time interaction (p  0.05). 
 
 
 
 
 
 
Figure 15: Chest press improvement in exercise groups (p  0.05). 
(*) = (p  0.05) Versus Baseline., (**) = Between-group differences (p  0.05) 
 
 
 
75
77
79
81
83
85
87
89
91
93
95
Baseline 12 months 24 monts 36 months
Waist Girth
Exercise Past-Iso Exercise & Past-Isoflavone Control
40
50
60
70
80
90
100
Baseline 12 months 24 months 36 months
Chest Press(kg )
Exercise Non-Exercise
*
* *
** **
 38 
 
 Figure 16: Squat strength improvement in exercise groups (exercise group x time 
interaction) (p  0.05). 
(*) = (p  0.05) Versus Baseline., (**) = Between-group differences (p  0.05) 
20
40
60
80
100
120
140
160
180
200
Baseline 12 months 24 months 36 months
Leg Strength (kg)
Exercise Non-Exercise
*
* *
****
   
3
9
 
Table 2. Bone Outcomes. 
Variable Exercise 
 
Past-Isoflavone 
 
Exercise & Past-
Isoflavone 
 
Control 
 
 Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mo 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 
mo 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 
mo 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 
mo 
Mean 
(SD) 
 
36 
mo 
Mean 
(SD) 
 
Lumbar Spine 
aBMD** 
0.94 0.94 0.93 0.95 0.95 0.94 0.96 0.95 0.94 0.97 0.98 0.97 
(0.11) (0.11) (0.11) (0.11) (0.11) (0.11) (0.11) (0.11) (0.11) (0.11) (0.11) (0.11) 
Total Hip 
aBMD** 
0.88 0.87 0.86 0.91 0.91 0.90 0.89 0.87 0.86 0.89 0.88 0.87 
(0.09) (0.10) (0.10) (0.09) (0.10) (0.10) (0.09) (0.09) (0.09) (0.09) (0.10) (0.10) 
Femoral Neck 
aBMD* 
0.72 0.71 0.70 0.77 0.75 0.74 0.74 0.72 0.72 0.74 0.73 0.73 
(0.08) (0.08) (0.09) (0.08) (0.08) (0.09) (0.08) (0.08) (0.09) (0.08) (0.08) (0.09) 
Trochanter 
aBMD 
0.67 0.66 0.65 0.70 0.69 0.68 0.69 0.68 0.67 0.67 0.68 0.66 
(0.08) (0.08) (0.09) (0.08) (0.08) (0.09) (0.08) (0.08) (0.09) (0.08) (0.08) (0.09) 
Whole Body 
aBMD* 
1.08 1.07 1.05 1.10 1.10 1.09 1.08 1.08 1.06 1.13 1.13 1.11 
(0.09) (0.08) (0.08) (0.09) (0.08) (0.08) (0.09) (0.08) (0.08) (0.09) (0.08) (0.08) 
Intertrochanteric 
Cross-sectional 
area* 
4.70 4.91 5.01 4.95 5.01 5.35 4.91 5.06 5.19 4.82 4.99 5.16 
(0.69) (0.79) (0.86) (0.69) (0.79) (0.86) (0.69) (0.79) (0.86) (0.69) (0.79) (0.86) 
Intertrochanteric 
CSMI* 
12.30 12.84 13.36 13.74 14.31 15.16 13.03 13.72 14.04 12.38 13.40 13.84 
(2.66) (3.11) (3.19) (2.66) (3.11) (3.19) (2.66) (3.11) (3.19) (2.66) (3.11) (3.19) 
Intertrochanteric 
Section 
Modulus* 
4.20 4.34 4.49 4.49 4.64 5.00 4.42 4.56 4.75 4.16 4.36 4.65 
(0.74) (0.86) (0.93) (0.74) (0.86) (0.93) (0.74) (0.86) (0.93) (0.74) (0.86) (0.93) 
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Shaft Cross-
sectional Area* 
4.18 4.35 4.48 4.57 4.62 4.79 4.51 4.54 4.73 4.44 4.51 4.81 
(0.56) (0.55) (0.62) (0.56) (0.55) (0.62) (0.56) (0.55) (0.62) (0.56) (0.55) (0.62) 
Shaft CSMI** 3.14 3.27 3.39 3.69 3.74 4.13 3.59 3.57 3.79 3.49 3.74 4.13 
(0.68) (0.67) (0.82) (0.68) (0.67) (0.82) (0.68) (0.67) (0.82) (0.68) (0.67) (0.82) 
Shaft Section 
Modulus* 
2.17 2.26 2.34 2.43 2.46 2.58 2.41 2.43 2.55 2.35 2.42 2.65 
(0.35) (0.34) (0.41) (0.35) (0.34) (0.41) (0.35) (0.34) (0.41) (0.35) (0.34) (0.41) 
Narrow Neck 
Cross-sectional 
Area* 
2.67 2.71 2.77 2.93 2.89 2.93 2.85 2.79 2.88 2.72 2.79 2.88 
(0.38) (0.40) (0.42) (0.38) (0.40) (0.42) (0.38) (0.40) (0.42) (0.38) (0.40) (0.42) 
Narrow Neck 
CSMI* 
2.09 2.18 2.25 2.43 2.42 2.56 2.27 2.29 2.39 2.04 2.21 2.70 
(0.46) (0.48) (0.93) (0.46) (0.48) (0.93) (0.46) (0.48) (0.93) (0.46) (0.48) (0.93) 
Narrow Neck 
Section Modulus 
1.25 1.28 1.32 1.41 1.41 1.46 1.34 1.32 1.38 1.25 1.29 1.36 
(0.22) (0.22) (0.23) (0.22) (0.22) (0.23) (0.22) (0.22) (0.23) (0.22) (0.22) (0.23) 
aBMD = Areal bone mineral density  
CSMI = cross-sectional moment of inertia 
Notes, Rows demarcated with * * indicate group x time interaction (see figures). 
Rows demarcated with * indicate a time main effect (p<0.05). 
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Table 3. Body Composition and Anthropometry. 
Variable Exercise 
 
Past-Isoflavone 
 
Exercise & Past-Isoflavone 
 
Control 
 
 Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mo 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mo 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mo 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mo 
Mean 
(SD) 
 
Whole Body 
Fat Mass 
 (kg) * * 
25 24 24  29 29 30 27 25 25 25  25  26  
(7) (7) (7) (7) (7) (7) (7) (7) (7) (7) (7) (7) 
Whole Body 
Lean Mass 
(kg) 
41  42  42 44 44  44  43 42  43 41 40  41 
(5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) 
Trunk Fat 
Mass 
(kg)* * 
12 11  11  14  14 15 13  12  12  12  12  12  
(4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4) 
Weight 
 (kg) * ** 
68 68  67  73  74 76  69 66 64  66 66 67 
(11) (10) (10) (11) (10) (10) (11) (10) (10) (11) (10) (10) 
Waist Girth 
(cm) * ** 
82 82  82 87  88  89 85  83  82  82  81 82 
(11) (10) (10) (11) (10) (10) (11) (10) (10) (11) (10) (10) 
%Fat * * 36  35  35  38  38 39   37 35 35 37 37 37  
(5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) (5) 
Notes, Rows demarcated with * * indicate exercise group x time interaction (see figures). 
Rows demarcated with *** indicate exercise group x isoflavone group x time interaction (see figures) 
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Table 4. Exercise Tests Outcomes. 
Variable Exercise 
 
Past-Isoflavone 
 
Exercise & Past-Isoflavone 
 
Control 
 
 Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mon 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mon 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mon 
Mean 
(SD) 
 
Baseline 
Mean 
(SD) 
 
24 mo 
Mean 
(SD) 
 
36 mon 
Mean 
(SD) 
 
Chest 
Press(kg)* * 
66  92 92 68 73 75 69 95  93 52 57 63 
(23.54) (23.86) (25.06) (23.54) (23.86) (25.06) (23.54) (23.86) (25.06) (23.54) (23.86) (25.06) 
Squat 
Strength 
 (kg)* * 
59.35 159.6 178.5 65 113.8 104.3 58.33 171.9 181.4 34 88 87 
(36.32) (54.32) (59.04) (36.32) (54.32) (59.04) (36.32) (54.32) (59.04) (36.32) (54.32) (59.04) 
Balance Time 
Average 
(seconds) * 
41.89 30.52 27.27 42.06 35.41 36.76 41.89 28.31 28.06 49.05 38.77 36.83 
(14.41) (12.35) (14.30) (14.41) (12.35) (14.30) (14.41) (12.35) (14.30) (14.41) (12.35) (14.30) 
Balance errors 2.30 1.78 1.81 2.97 3.62 2.91 2.27 1.92 2.13 2.05 2.00 2.27 
(2.23) (2.20) (2.54) (2.23) (2.20) (2.54) (2.23) (2.20) (2.54) (2.23) (2.20) (2.54) 
Walking Test 
(seconds) * 
52.3 50 52.3 51.88 50.24 53.71 51.21 49.67 52 54.45 52.82 54.09 
(6.37) (5.92) (6.18) (6.37) (5.92) (6.18) (6.37) (5.92) (6.18) (6.37) (5.92) (6.18) 
Notes, 
Rows demarcated with * * indicate exercise group x time interaction (see figures). 
Rows demarcated with * time main effect (p<0.05). 
5.3. Adverse Events and Symptoms.  
There were no serious adverse events recorded during the extension study. The frequency of non-serious adverse effects from baseline 
until the second year was reported in a previous study (Chilibeck et al., 2013). 
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6. Discussion 
The present study is the first to examine the effect of exercise training among 
postmenopausal women over a three-year period. Although there have been previous 
studies conducted to demonstrate the benefits of exercise training, this is the first to show 
the effect of persistent exercise training over a three-year duration following the cessation 
of isoflavone. The specific aim of this study was to investigate the BMD at lumbar spine 
and proximal femur in postmenopausal women after cessation of isoflavone therapy, but 
with continuation of exercise training. We hypothesized that an additional year of exercise 
training after cessation of isoflavone therapy, or continued exercise training for an 
additional year in women who never received isoflavone in the first study (Chilibeck et al., 
2013), would be effective in increasing lumbar spine and proximal femur aBMD as 
compared to participants who did not exercise and did not take isoflavone. Moreover, we 
also hypothesized that an additional year of exercise training after cessation of isoflavone 
therapy, or continued exercise training for an additional year in women who never received 
isoflavone in the first study (Chilibeck et al., 2013),  would be effective in improving bone 
geometry as compared to the control groups who did not exercise.  
The results of the present study indicated that there were significant differences in 
the aBMD, and geometry between the exercise and non-exercise groups. Unexpectedly, 
the exercise groups lost more aBMD at the lumbar spine and total hip in comparison to the 
non-exercise groups.  Although the majority of data supports the idea that exercise can 
delay or stabilize osteoporosis, and in fact exercise is used as one of the first line of 
treatment for osteoporosis (Papaioannou et al., 2010), the results of the present study were 
at odds with this guideline. Our findings, however, are not unusual.  
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A study similar to ours, but without isoflavone supplements or cessation, 
researched the effects of exercise (home-based daily exercise; 20 min d-1), over a 30-month 
period in post-menopausal women (Korpelainen, Keinänen-Kiukaanniemi, Heikkinen, 
Väänänen, & Korpelainen, 2006). The authors of this study measured the aBMD in the 
femoral neck and trochanter and found that there was a slight decrease in the control group 
while there were no changes in the exercise group. In both groups, as they aged, there was 
significant bone loss at the radius and calcaneus. The authors concluded that exercise, 
besides improving physical conditioning, had little effect on the aBMD and the other bone 
variables measured. There are a number of reasons as to why the author of this study did 
not find differences between the exercise and non-exercise group in terms of aBMD, and 
in bone quality and architecture. First, bone expansion is dependent on factors such as age, 
gender, hormonal variables, stress and weight changes (Korpelainen et al., 2006). 
Furthermore, it has been found that obesity has a protective effect against osteoporosis in 
post-menopausal women (Albala et al., 1996). The explanation for this is that excess fat 
leads to an increase in free sex steroids within the body, and this in turn stimulates 
osteoblasts to form bone mass. Moreover, although it may seem counter intuitive, the 
excess weight in obese people means that they are constantly exerting mechanical loading 
on their bones and this may lead to further proliferation of osteoblasts. This means that as 
people lose weight, the mechanical stress they exert on the bones decreases. Secondly, as 
people age there is an aBMD decline of 3% to 5% per year in the decade after menopause 
so that over the length of the study, even though there may have been bone mass which 
formed due to the stimulating effects of exercise, it was insufficient to offset the declines 
(Josse et al., 1996).  
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    In the present study, any benefits or negative effects of isoflavone in the third year 
can be discounted as the intestinal half-life of soy isoflavones is very short, varying from 
3.3 to 7.5 h (Xu, Harris, Wang, Murphy, & Hendrich, 1995). This is because the bacteria 
in the gut break down the isoflavone.  Therefore, any residual effects of isoflavone over 
the one year period of the present study can be discounted and the only effect measured 
was that of exercise on bone. Overall, these results indicate that exercise had no benefit on 
aBMD beyond the first two years of training (as indicated in the Chilibeck et al. (2013) 
study) and the removal of isoflavone supplements did not affect this result. 
 In the present study it was found that there were time main effects for aBMD 
(decreasing) and for geometric properties (increasing). This finding can be explained by 
the fact that although there is a net loss of aBMD in both men and women after maturity, 
there have been reports of increased bone thickness with aging due to bone growth on the 
periosteal, or exterior of the bone surface (Weaver et al., 2016). The majority of studies 
have examined bone modelling and bone loss at the endocortical, or the interior of the bone, 
and very few at the periosteal (Szulc, Seeman, Duboeuf, Sornay‐Rendu, & Delmas, 2006). 
It is known that bone formation occurs on both the periosteal and endocortical surfaces 
with bone deposition on the former resulting in an increase in the external diameter. During 
the growth phase, periosteal apposition surpasses endocortical resorption so that there is a 
net thickening and elongation of the cortex. During aging, however, it may be that 
periosteal development continues and supersedes endocortical bone loss so that there is 
either no net loss of bone and strength or that there is an increase in bone development on 
the exterior surface thereby leading to an increase in bone width. A number of studies have 
reported increases in pelvic and L4 lumbar vertebra growth (Berger, May, Renner, Viradia, 
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& Dahners, 2011), femoral neck (Johnson, Renner, & Dahners, 2012), and the hand bones 
(Kalichman, Malkin, Seibel, Kobyliansky, & Livshits, 2008).  
 In one of the few studies on periosteal development, the authors studied bone mass 
changes and bone geometry and strength in 821 women divided into four groups: 151 
premenopausal, 33 perimenopausal, 279 postmenopausal women, and 72 postmenopausal 
women receiving HRT (either equine estrogens or transdermal 17β‐estradiol) (Szulc et al., 
2006). The authors found that while in premenopausal women there was an increase in the 
radius width, it only partly offset cortical bone loss. In all of the other groups, the authors 
found that there was a decrease in both periosteal and endocortical bone resorption leading 
to reduced aBMD and strength as the women aged. However, the HRT therapy was 
effective in slowing bone loss and strength. In another study, the authors measured, besides 
other factors such as aBMD, subperiosteal and endocortical width (cm) at specific locations 
of the proximal femur in white (non-Hispanic) group of 2719 men and 2904 women 
ranging in age from 20 to 99 (Beck, Looker, Ruff, Sievanen, & Wahner, 2000). The authors 
found that in females the width, or Z, at the narrow neck and the shaft regions was constant 
until the age of 50 after which there was a slight decline but at a rate lower than aBMD. In 
males there was a marginal decline in the narrow neck Z until the fifth decade after which 
it remained constant but this was followed by an increase as the age increased. In both 
sexes, although there was a decline in aBMD there was a concomitant expansion in 
subperiosteal diameter in both sexes and in both regions. The authors concluded that 
although there was a loss in aBMD, the increases in width may have offset the reduction 
in mechanical strength caused by aBMD loss. The aforementioned reports suggest that 
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further work needs to be conducted in order to fully elucidate bone loss and modelling as 
one ages so that fracture risk decreases as one ages. 
 Another possible explanation for bone geometric increase in the non-exercise group 
is the inaccuracies in the DXA bone measurements based on the changes in soft tissue and 
its distribution within the scanned region. In an in vivo study by Bolotin et al., (2001), it 
was found that DXA scans in regions where there were two absortiometrically 
distinguishable components, the BMD error was as high as 20% (Bolotin, Sievänen, 
Grashuis, Kuiper, & Järvinen, 2001). The authors noted that the errors were especially high 
in subjects with osteoporotic bones, such as in postmenopausal women and the elderly. 
This error, in the authors’ opinion, was attributable to the body fat in the region. In a follow 
up study to the preceding one, the authors measured BMD in regions where the body fat 
and the lean muscle tissue was unevenly distributed and reported BMD errors ranging from 
20 to 50 percent (Bolotin, Sievänen, & Grashuis, 2003). In a clinical setting, this means 
that the errors which can occur when testing individuals for BMD can be highly variable 
and are dependent on the fat and lean muscle distribution within the scanned region. In the 
present study, there were no statistically significant changes in lean tissue mass, body 
weight and waist girth in the non-exercise groups but there was a decrease in total body fat 
mass, percent fat, and trunk fat mass in the exercise group. Given this data, the BMD 
measurement errors within the non-exercise group should have offset (e.g. since the fat and 
lean mass did not change from the baseline to the third year, any measurement errors should 
have been offset).  
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6.1. Body Weight and aBMD.  
The results in the present study showed a statistically significant decrease in body 
weight in the exercise + Past Iso group (Figure 13) and a significant loss of whole body fat 
mass (Figure 10). This finding is in line with other reports in the literature where the loss 
of body weight correlated to a greater loss in aBMD. In a recent study of 165 post-
menopausal women, the researchers measured body weight, BMI and aBMD of the spine 
and proximal femur and found that both body weight and BMI positively correlated with 
aBMD (Mir et al., 2017). In fact, the authors concluded that increased body weight and a 
greater BMI protected the women against osteoporosis. The rationale of the authors for this 
conclusion was that the increased mass in obese and overweight people led to mechanical 
loading, or inadvertent weight or load bearing exercise, which stimulated the osteoblasts. 
Moreover, the authors noted that adipose tissue is a source of estrogens and that this too 
may have had a positive effect on aBMD in postmenopausal women. 
Similarly, several other studies have indicated that BMI can be used to identify the 
risk of osteoporosis in postmenopausal women (Hendrijantini, Alie, Setiawati, Astuti, & 
Wardhana, 2016; Ravn et al., 1999).  As with the study above, it was noted that thinner 
women are at a greater risk for postmenopausal bone loss as compared to heavier women. 
These findings support our results that the women in the exercise group lost significantly 
more body fat from baseline to the third year and showed greater aBMD loss as compared 
to women in the non-exercise group. Other studies too have come to the same conclusion 
that weight loss is one of the leading causes of bone loss in older populations (Albala et al., 
1996; Khosla, 2013; Villareal et al., 2011).  
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 Although there seems to be strong evidence suggesting that a higher weight can 
mitigate the risks of osteoporosis, the diseases linked with a high BMI or fat mass may 
offset the benefits. A number of serious diseases and increased mortality have been 
attributed to being overweight/obese and include many cardiovascular diseases (CVDs) 
such as high blood pressure, coronary heart disease, congestive heart failure, stroke, high 
total cholesterol and triglycerides in blood serum, and others such as diabetes mellitus 2, 
and cancer (Hensrud & Klein, 2006). A higher trunk fat mass, often measured by waist 
circumference, correlates with lipid measures that are associated with increased CVD so 
that the loss of fat mass, especially in the trunk region, could reduce CVD risk (Haslam, 
Sattar, & Lean, 2006; Vatanparast et al., 2009). Furthermore, with increased obesity, a 
body’s routine functional capacity such as sitting/standing, walking, and balance control 
are affected so that there are greater risks for falling (Pataky, 2014; Wee et al., 2011). 
Economically, too, there are benefits to losing fat mass as overweight adults have health 
care costs that are 10-20% higher as compared to people with normal weights (Hammond 
& Levine, 2010).  
 
6.2. Exercise and Fitness Parameters.  
 As was expected, the exercise groups improved in strength as compared to the non-
exercise groups (Figures 15, 16, and Table 4). The participants in the exercise groups 
improved their fitness parameter fitness parameter (body composition, chest press and leg 
strength) from the baseline and this continued into the third year of the study. These results 
were to be expected as, with exercise, the muscles adapt and become stronger (Morgan, 
Cobb, Short, Ross, & Gunn, 1971). A recent study examined the incidences of falls and the 
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effects of exercise on leg strength, walking speed, and backward walking (dynamic balance) 
in post-menopausal women aged between 70 to 80 (Patil et al., 2015). The authors found 
that, besides exercise reducing falls by 50 percent, there were statistically significant 
(P < 0.05), improvements in all of the aforementioned parameters as compared to the non-
exercise group. Another study similar to the present one found that over a 30 months period, 
postmenopausal women who exercised had statistically significantly greater leg strength, 
walking speed, and in the distance they were able to walk in two minutes as compared to 
those who did not (Korpelainen et al., 2006). While the authors did not find any positive 
effects on aBMD, or bone geometry, they did note that exercise helped the women to be 
more able to maintain their balance and this may lead to a lower fracture incidence rate as 
compared to those who did not exercise.  
 It was found that at the end of the third year, the exercise groups were 65% stronger 
than the non-exercise groups. This is a substantial difference and if extended into older age, 
is highly likely to have benefits for increasing functional abilities. A 20% difference in 
strength is predictive of differences in functional impairments; therefore, the 65% 
difference in strength could be considered clinically significant (Brill, Macera, Davis, Blair, 
& Gordon, 2000). As noted above, besides increasing dynamic balance and strength, 
exercise also helps to reduce falls and the severity of injuries. Besides these benefits, 
exercise is also known to prevent and decrease the risks of CVD and death in 
postmenopausal women (Kushi et al., 1997). In fact, regular physical activity is known to 
reduce the risk, by 20% to 30%, of at least 25 chronic medical conditions (Warburton & 
Bredin, 2018), including type 2 diabetes, depression, and cancer of the breast and colon 
(Thompson et al., 2003).  
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 Our study found that waist girth and body mass decreased in the exercise + past 
isoflavone group with no change in the other groups. These results are similar to a six 
month long clinical trial where the effects of exercise training combined with isoflavones 
supplement were measured on 34 postmenopausal women (Lebon, Riesco, Tessier, & 
Dionne, 2014). The authors found that in the combined therapy group there was a decrease 
in total fat mass with decreases in hip, leg and trunk circumferences. This suggests that 
isoflavones may have synergistic effects with exercise for improving some components of 
body composition 
 
6.3. Strengths, Limitations and Future Considerations. 
 One of the limitations of the present study was the small number of participants. 
Regardless, the present study is the only study, to the author’s knowledge, which 
investigated the effect of exercise training in postmenopausal women on aBMD over a 
three-year period using DXA scan as a primary tool of investigation. No other study has 
investigated the effects of a resistance-training program greater than 2 years in duration on 
aBMD (Howe et al., 2011). Another limitation may be that using DXA for monitoring the 
aBMD in the elderly may not be the best way to monitor and measure aBMD (Engelke, 
Libanati, Fuerst, Zysset, & Genant, 2013), especially given the fact that there are now more 
sensitive and accurate instruments, such as those utilizing computed tomography, which 
may be more useful and are able to detect minute differences which were imperceptible 
with DXA.    
Future studies could research if the high dose of isoflavones supplements had a 
greater affinity towards the β estrogen receptor and if this blocked the stimulating effects 
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of exercise on bone by downregulating bone synthesis (Saxon, Robling, Castillo, Mohan, 
& Turner, 2007). This is further supported by the fact that it has been reported that a low 
dose soy isofalvone supplement resulted in aBMD increases in early postmenouaposal 
women as compared to high dose isofalvone (Huang et al., 2006).  ).  A study researching 
aBMD in postmenopausal women, with one control group and two other groups who 
receive a low-level supplement and the second receiving a high dose, may be able to 
unravel if varying dosages of isoflavone has any effect on aBMD. 
6.4. Conclusion.  
 The results of the present study showed that exercise had no benefit on aBMD in 
the third year of the study as the bone loss in the exercise group was greater than the non-
exercise group.  The exercise program, however, improved body composition (i.e. reduced 
fat mass, trunk fat, and percent fat) and increased strength of the participants from the 
baseline to year 3.  
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8. Appendices 
8.1. Consent Form 
 
Title of the study: Effect of exercise training beyond 2 years on prevention of osteoporosis 
Researchers: Philip D. Chilibeck, Ph.D., Associate Professor, College of Kinesiology, 
University of Saskatchewan (966-1072). 
Muhedeen Abdulmula, Master Student, College of Kinesiology, University of 
Saskatchewan   
 
 You are being asked to participate in an extension to a research study. Currently 
you are performing resistance training exercise and walking OR flexibility exercises and 
taking a soy-based nutritional supplement or placebo. We are inviting you to continue 
taking part in the exercise portion of this study for one more year. You will stop taking the 
isoflavone or placebo during this study extension 
 Before you decide, it is important for you to understand what the research involves.  
This consent form will tell you about the study, why the research is being done, what will 
happen to you during the study and the possible benefits, risks and discomforts.  If you 
wish to participate, you will be asked to sign this form.  Your participation is entirely 
voluntary, so it is up to you to decide whether or not to take part in this study. If you do 
decide to take part in this study, you are free to withdraw at any time without giving any 
reasons for your decision nor will this affect the medical care you are currently receiving 
or your access to services at the university. Please take time to read the following 
information carefully and to discuss it with your family, friends, and doctor before you 
decide. 
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Purpose of the study 
  Exercise training has small benefits for increasing bone mineral density and 
therefore increasing bone strength. Very few studies have evaluated the effects of exercise 
training for longer than 2 years on bone mineral density. The purpose of this study is to 
determine the effects of 3 years of exercise training on bone mineral density. 
 
Possible benefits of the study 
 Possible benefits include an increase in bone mineral density, an improvement in 
bone quality, a loss of body fat, an increase in muscle mass, or an increase in flexibility. 
These benefits are not guaranteed.  
 
Procedures to be followed  
 You will discontinue the soy-based nutritional supplement or placebo you are 
currently taking, but will continue with the exercise portion of the study. This involves 
either strength training twice per week (45 minutes to an hour each session) and brisk 
walking four times per week (about 30 minutes each time) OR flexibility exercises (20-
30 minutes per day) four days per week.  
 
12 Month follow-up measurements 
 Your bone mineral density and body composition will be measured by dual-energy 
x-ray absorptiometry. The bone in your lower leg and wrist will be measured by ultrasound 
(to measure bone quality). Exercise testing will be performed. This will involve 
determining the maximal amount of weight you can lift on several exercises, a walking test 
over 80 meters, a flexibility test, and a test of balance. You will be required to fill out 
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questionnaires to assess your food intake and physical activity levels. Testing is done in 
one session and will require about 2 hours of your time.  
With your permission, your family physician will be informed of your enrolment and of 
your test results. 
 
Foreseeable risks, side effects and discomfort 
 There is some radiation exposure with the dual energy x-ray absorptiometry. This 
is equivalent to the amount of radiation you would receive during a return airplane flight 
to Toronto. 
 There is a risk of injury during exercise testing or training. This will be minimized 
by proper warm-up procedures and supervision by qualified exercise trainers. There may 
be unforeseen risks during the study or after the study is completed. 
You are free to withdraw from the study at any time and this withdrawal will not affect 
access to health care or other services. 
 
Alternatives to this study 
 You do not have to participate in this study to improve your bone mineral density. 
You can join any gym and receive instructions from staff on a proper exercise training 
program. You can also take various medications such as HRT or bisphosphonates to 
improve your bone mineral density. 
 
Research-Related Injury 
 There will be no cost to you for participation in this study. In the event you become 
ill or injured as a result of participating in this study, necessary medical treatment will be 
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made available at no additional cost to you. By signing this document you do not waive 
any of your legal rights. 
 
Confidentiality  
 Precautions will be taken to protect your anonymity during the study. All data 
collected will be stored in a locked office in the College of Kinesiology. While absolute 
confidentiality cannot be guaranteed, every effort will be made to ensure that the 
information you provide for this study is kept entirely confidential.  Your name will not be 
attached to any information, nor mentioned in any study report, nor be made available to 
anyone except the research team.  It is the intention of the research team to publish results 
of this research in scientific journals and to present the findings at related conferences and 
workshops, but your identity will not be revealed. 
 
If you have questions concerning the study you can contact Dr. Philip Chilibeck at 966-
1072, 343-6577, or 230-3849 (24 hour number). 
 
If you have any questions about your rights as a research subject or concerns about the 
study, you should contact the Chair of the Biomedical Research Ethics Board, c/o the 
Office of Research Services, University of Saskatchewan at (306) 966-4053. 
 
If, during the course of this study, new information becomes available that may be related 
to your willingness to continue to participate, this information will be provided to you by 
the investigator. 
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Your participation in the research is entirely voluntary. You are free to withdraw from this 
study at any time and this withdrawal will not affect your relationship with the researchers 
or your standing at the university. If you choose to enter the study and then decide to 
withdraw at a later time, all data collected about you during your enrolment in the study 
will be retained for analysis.   
 
Please read the following before signing this consent form: 
 I have read or have had this read to me and understood the research subject 
information and consent form.  
 I have had sufficient time to consider the information provided and to ask for advice 
if necessary.  
 I have had the opportunity to ask questions and have had satisfactory responses to 
my questions.  
 I understand that all of the information collected will be kept confidential and that 
the result will only be used for scientific objectives.  
 I understand that my participation in this study is voluntary and that I am 
completely free to refuse to participate or to withdraw from this study at any time 
without changing in any way the quality of care that I receive.  
 I understand that I am not waiving any of my legal rights as a result of signing this 
consent form.  
 I understand that there is no guarantee that this study will provide any benefits to 
me (if applicable).  
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 I have read this form and I freely consent to participate in this study.   
 I have been told that I will receive a dated and signed copy of this form.   
 
Please notify my primary care physician of my participation in this study:  
Yes_____ 
No______ 
 
Research Subject’s Signature:___________________   
 
 
Signature of the Individual responsible for conducting the consent process: 
 
______________________  
 
 
Date: ______________________ 
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8.2. Researcher’s Summary Form. 
 
 
       
http://www.usask.ca/research/ethical.shtml 
  
 REB File Number:
 _____________ 
 
PROJECT TITLE: Effect of exercise training beyond 2 years on prevention of osteoporosis 
 
PRINCIPAL INVESTIGATOR:   Philip D. Chilibeck, Ph.D., Associate Professor 
                                                                  Muhedeen Abdulmula, Master Student 
 
DEPARTMENT:  College of Kinesiology 
 
SUB-INVESTIGATOR(S):   
 
DEPARTMENT: College of Kinesiology 
   
RESEARCH WILL BE CONDUCTED AT: College of Kinesiology 
 
________________________________________________________________________
____ 
 
1. Hypothesis (State briefly the nature and purpose of the research proposal, and the 
proposition the research is seeking to uphold. What potentially useful knowledge or 
clarification about therapeutic options will be advanced to justify the participation of 
human subjects in this research project?) 
 
We hypothesize that: 
 
Post-menopausal women participating in an extended resistance training and walking 
exercise program will achieve a greater increase in bone mineral density than women 
participating in an extended flexibility program. 
 
2. Academic Validity (Provide evidence that the scientific reasoning and design of the 
project are sufficiently sound to meet the objectives of this project. Provide your own 
comments and if possible those resulting from peer review.  Indicate if any other 
committee or agency has assessed the project’s scientific validity):   
 
 
Biomedical Research Ethics Board (Bio-REB) 
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Currently we are running a study (Bio#03-1077) in which 351 post-menopausal women 
are taking part in either a resistance training and walking exercise program or a 
flexibility exercise program. They have also been randomized to receive a soy-based 
nutritional supplement or a placebo. Bio#03-1077 involves 2 years of the intervention, 
with the primary outcome of bone mineral density. The first subjects in this study were 
enrolled in December 2004 and therefore are close to completing the initial study. No 
study has investigated the effects of a resistance training program greater than 2 years 
duration on bone mineral density (Bonaiuti et al., Cochrane Database Systematic 
Review, 2002). Bone turns over slowly; therefore, the increases observed with exercise 
training are usually only about 1-2% per year (Bonaiuti et al., 2002). A 5% increase in 
bone mineral density is necessary for a clinically significant reduction in chance of 
fracture (Guyatt et al. Endcrinology and Metabolism Clinics of North America, 2002).  
We want to extend the exercise portion of the current study to investigate the effects of 
3 years of resistance training on bone mineral density. Women completing Bio#03-
1077 will stop taking their soy-supplement and placebo, but continue with the exercise 
portion of the study. While stopping the soy-supplement or placebo may have an effect 
on their bone mineral density, there should be an approximate equal number of women 
originally randomized to the resistance training and flexibility groups who are also 
randomized to supplement and placebo; therefore, the effect of stopping isoflavone or 
placebo should be equal across the two different exercise groups. 
 
If applicable, please indicate whether TPD approval has been obtained: 
 
 Yes _____  No _____ Pending _____  N/A __x___ 
 
3. Funding (indicate the source of funds supporting the research.  If externally funded, 
state whether the grant or contract is still in application, or has already been awarded): 
 
Residual CIHR funds from Bio #03-1077 will be used for the extension study 
 
 
4. Disclosure of Potential Conflicts of Interest (indicate any motivation or incentives for 
conducting this study that arise external to the objectives of the study, e.g., will the 
investigator or institution be paid to conduct this research project? Note:  The consent 
form should also include an introductory disclosure of potential conflict of interest 
statement, where applicable, indicating that this is a medical research study for which 
the study doctor, the institution, or both are being paid): 
 
None 
 
 
5. Subjects  
a) Target Population (e.g., age, gender, medical condition, target enrollment, 
significant inclusion/exclusion criteria): 
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Post-menopausal women currently participating in Bio 03-1077 will be invited to 
continue with the exercise portion of the study. The main exclusion criteria are that 
they have to refrain from taking any medications (i.e. bisphosphonates or hormone 
replacement therapy) that affects bone mineral density. 
 
b) Proposed Strategies for Recruitment (e.g., use of advertisements, brochures, 
physician patient records):  
 
Subjects currently participating in Bio 03-1077 will be invited to participate in the 
extension. 
 
6. Procedures (clearly identify treatment allocation design, and describe the medical and 
other procedures to be followed in obtaining research data, including questionnaires): 
 
Subjects will continue to perform the exercise programs they are currently doing in Bio 03-
1077. This involves either strength training twice per week (45 minutes to an hour each 
session) and brisk walking four times per week (about 30 minutes each time) OR flexibility 
exercises (20-30 minutes per day) four days per week.  
 
Subjects will be measured for bone mineral density at their lumbar spine, hip, and whole 
body by dual energy X-ray absorptiometry, bone quality at the tibia and radius by 
ultrasound, strength for squat and bench press exercise, flexibility (sit and reach test), 
walking speed, and balance after 12 months. Subjects will be asked to fill out a food 
frequency questionnaire and physical activity questionnaire at 6 and 12 months. All these 
procedures are identical to those approved for Bio 2003-1077. 
 
 
7. Time Period (indicate the dates when the research project is expected to begin and to 
be completed.  A final status report must be filed with the Ethics Office once data 
collection from the last subject is complete. The Ethics Office should be notified once 
the study site is closed.): 
 
The extension study will start in December 2006. The latest the study would run is April 
2009 because the last women to enter Bio 2003-1077 entered in April 2006 (and therefore 
will complete Bio 2003-1077 in April 2008). 
 
 
8.    Data Storage (In accordance with recommended guidelines provide a statement 
outlining the procedures you will use to store securely the research data.  State how 
long and where the data will be stored and identify the person who will be assuming 
responsibility for data storage): 
 
Data will be stored in a locked office in the college of Kinesiology for a period of 25 
years. 
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9. Consent Form (include a copy of the consent form and/or any study information that 
will be used.  If not using a consent form give reasons why).   
Attached 
 
 
9. Signatures 
  
  
 ______________________________ ______________________________ 
 Principal Investigator    Phone 
 
 ______________________________ ______________________________ 
 Fax       e-mail 
 
 
 _______________________________________ 
 Department Head, Dean, Director, or Administrative Head   
 
 
10. Contact Person and Mailing Address for Correspondence: 
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8.3. Study Renewal, Extension Study (06-234). 
 
 
*Note, if your study is complete please fill out the study closure form available at: 
http://www.usask.ca/research/files/index.php?id=22  
Please type in your responses, print, and then send the original signed copy to our office. Do not fax. 
Double click on boxes to check. 
1. Title: Effect Of Exercise Training Beyond 2 Years On Prevention Of Osteoporosis 
2. Bio #:  06-234 3: Protocol #:  
4: Expiry Date: November 28, 2008 5: Clinical Trial Registration Number (If applicable):  
6. Contact Information: Philip Chilibeck 
 Name: Department: Phone Number, Email, Fax Number  
(Provide only if different from previously submitted information): 
Principal 
Investigator: 
Philip Chilibeck Kinesiology 966-1072, phil.chilibeck@usask.ca, 966-6464 
 
Contact 
Person: 
   
 
7. Sponsor/Funding Agency: CIHR 
8. Indicate whether delegated or full board review is required for this renewal.  
 Delegated Review (Please indicate which of the following apply) 
          Research involves no more than minimal risk 
          No research subjects have been enrolled in the study 
          Research remains open only for the long term follow up of participants 
          Remaining research is limited to data analysis 
 Full Board Review: 
           Regulatory/Sponsor requirement [e.g. US Federal Agency (e.g. NIH) or some sponsoring organization (e.g. NCIC, COG)] 
           Other (please indicate):  
9. Did the initial protocol require a “No Objection Letter” (NOL) from Health Canada?       Yes              No 
If Yes, please submit a copy of the original “NOL” if not already submitted.     
  Already submitted            Attached to renewal             
10. Location where research will be conducted (if different from previously submitted information): 
College of Kinesiology, Williams Building 
11. Does this research involve another institution?    Yes             No 
12. Is there interim analysis by a data safety monitoring board (DMSB) or some monitoring committee?    Yes            No 
Has there been a report from a DMSB or safety monitoring committee in the last year?       Yes              No 
If Yes, what was the outcome?    Continue study as planned              Modifications were suggested 
                                                             Close study temporarily                  Close study permanently 
13. Have there been any changes to the study (study design, changes in recruitment material, procedures, consent process,) that have 
not already been reviewed and approved by the Bio-REB?       Yes            No 
If Yes, please submit an amendment. 
14. Please indicate which version of the consent form(s) is(are) currently being used (date and/or version number).  
November 8, 2006 
Biomedical Research Ethics 
Board Study Renewal Form  
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15. Have there been any changes in research personnel, such as principal investigator, sub-investigators, Clinical Research Assistants, 
residents or students?    Yes            No 
If Yes, please list the former/new personnel and position. 
16. What is the current status of the study? (Please mark all that apply) 
  Recruitment has not yet started.  
  Research participants are currently being recruited. 
  Recruitment is closed. 
  Recruitment is closed and data collection involving participants is on-going.  
       What was the original number of participants to be recruited? _268______ 
       How many participants have been screened? __268_____ 
       How many participants were enrolled? ___107____ 
       How many research participants are currently in the study and receiving treatment?  __54______ 
       Is there a significant change in anticipated enrollment? Is yes, please explain.       Yes              No 
 
  The data collection is complete except for long-term follow-up of participants. 
       How many participants are currently not receiving treatment but still in the follow-up stage of the study? ________ 
  The data collection is complete, remaining research activities are limited to data analysis only. 
  The study is closed (Please complete the Biomedical REB Study Closure Form) 
17.  How many research participants have been withdrawn from or discontinued the study? ___11_____ 
 Please provide a reason for each withdrawal (if known): 
  Need for Other Treatment, number _____                                   Withdrawn Consent/Dropped Out, number: _11_____      
  Serious Adverse Event, number: ______                                       Other, number _____ (Specify reason, if known) 
18. Since receiving original ethics approval, have any ethical concerns arisen?     Yes              No 
If Yes, please describe concerns in detail. 
 
19. Have there been any serious adverse or unexpected events at this site?  
  No serious adverse events              Expected serious adverse events only              Unexpected serious adverse events  (Please 
attach a Serious Adverse Event Report for any unreported unexpected serious adverse events.) 
20. Were there major protocol deviations:    Yes              No 
Please attach a Protocol Deviation Report form for any unreported major protocol deviations. 
21. Have any findings, new information or study modifications changed the risk level of this study for current and future 
participants?     Yes              No 
 If Yes, explain the changes made, how participants will be notified and whether or not participants will be re-consented or refer to 
approved or submitted protocol amendment. 
23. Provide a brief summary of study progress.  Of the 268 subjects who completed bio#03-1077, 107 volunteered to continue with the 
exercise training program. Fifty-four of these participants remain in the study. 
 
24. Indicate the expected closure date of this study. November 30, 2009 
 
 
 
 
____________________________________   ______________________________ 
Signature of Principal Investigator    Date 
 
 
 
 
 
 
 
 
  72 
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